Cargando…
Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
Immune checkpoint inhibitors (ICIs), pembrolizumab in particular, have been shown to be vastly more efficacious than traditional cytotoxic or platinum-based chemotherapies in the treatment of non-small cell lung cancer (NSCLC). While there are plenty of data showing their efficacy and safety profile...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056863/ https://www.ncbi.nlm.nih.gov/pubmed/36983011 http://dx.doi.org/10.3390/ijms24065938 |
_version_ | 1785016227062611968 |
---|---|
author | Shalata, Walid Zolnoorian, Jeremy Migliozzi, Gabrielle Jama, Ashraf Abu Dudnik, Yulia Cohen, Ahron Yehonatan Meirovitz, Amichay Yakobson, Alexander |
author_facet | Shalata, Walid Zolnoorian, Jeremy Migliozzi, Gabrielle Jama, Ashraf Abu Dudnik, Yulia Cohen, Ahron Yehonatan Meirovitz, Amichay Yakobson, Alexander |
author_sort | Shalata, Walid |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs), pembrolizumab in particular, have been shown to be vastly more efficacious than traditional cytotoxic or platinum-based chemotherapies in the treatment of non-small cell lung cancer (NSCLC). While there are plenty of data showing their efficacy and safety profiles, very little exists about the long-term effects of pembrolizumab. We compiled all patients with NSCLC who were treated with pembrolizumab at our institution and had progression-free survival (PFS) of at least 2 years during or after the treatment period. Within this group, we examined the long-term rates of PFS and overall survival (OS), side effect profiles, treatment, and overall disease course up to 60 months after starting treatment. This study included 36 patients with median (range) follow up times from treatment initiation in months as follows: 36 (28–65) overall; 39.5 (28–65) for adenocarcinoma; and 36 (30–58) for squamous cell carcinoma. The median (range) of OS and PFS (months) was comparable for adenocarcinoma, 36 (23–55); and squamous cell carcinoma, 35.5 (28–65). Overall, pembrolizumab shows remarkable long-term safety and efficacy in NSCLC patients. In patients who show an initially strong response and can make it to 24 months of PFS, disease progression after this period seems increasingly unlikely. |
format | Online Article Text |
id | pubmed-10056863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100568632023-03-30 Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience Shalata, Walid Zolnoorian, Jeremy Migliozzi, Gabrielle Jama, Ashraf Abu Dudnik, Yulia Cohen, Ahron Yehonatan Meirovitz, Amichay Yakobson, Alexander Int J Mol Sci Article Immune checkpoint inhibitors (ICIs), pembrolizumab in particular, have been shown to be vastly more efficacious than traditional cytotoxic or platinum-based chemotherapies in the treatment of non-small cell lung cancer (NSCLC). While there are plenty of data showing their efficacy and safety profiles, very little exists about the long-term effects of pembrolizumab. We compiled all patients with NSCLC who were treated with pembrolizumab at our institution and had progression-free survival (PFS) of at least 2 years during or after the treatment period. Within this group, we examined the long-term rates of PFS and overall survival (OS), side effect profiles, treatment, and overall disease course up to 60 months after starting treatment. This study included 36 patients with median (range) follow up times from treatment initiation in months as follows: 36 (28–65) overall; 39.5 (28–65) for adenocarcinoma; and 36 (30–58) for squamous cell carcinoma. The median (range) of OS and PFS (months) was comparable for adenocarcinoma, 36 (23–55); and squamous cell carcinoma, 35.5 (28–65). Overall, pembrolizumab shows remarkable long-term safety and efficacy in NSCLC patients. In patients who show an initially strong response and can make it to 24 months of PFS, disease progression after this period seems increasingly unlikely. MDPI 2023-03-21 /pmc/articles/PMC10056863/ /pubmed/36983011 http://dx.doi.org/10.3390/ijms24065938 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shalata, Walid Zolnoorian, Jeremy Migliozzi, Gabrielle Jama, Ashraf Abu Dudnik, Yulia Cohen, Ahron Yehonatan Meirovitz, Amichay Yakobson, Alexander Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience |
title | Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience |
title_full | Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience |
title_fullStr | Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience |
title_full_unstemmed | Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience |
title_short | Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience |
title_sort | long-lasting therapeutic response following treatment with pembrolizumab in patients with non-small cell lung cancer: a real-world experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056863/ https://www.ncbi.nlm.nih.gov/pubmed/36983011 http://dx.doi.org/10.3390/ijms24065938 |
work_keys_str_mv | AT shalatawalid longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience AT zolnoorianjeremy longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience AT migliozzigabrielle longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience AT jamaashrafabu longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience AT dudnikyulia longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience AT cohenahronyehonatan longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience AT meirovitzamichay longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience AT yakobsonalexander longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience |